» Articles » PMID: 33671422

and Its Virulence Factors HO and Pneumolysin Are Potent Mediators of the Acute Chest Syndrome in Sickle Cell Disease

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2021 Mar 6
PMID 33671422
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Sickle cell disease (SCD) is one of the most common autosomal recessive disorders in the world. Due to functional asplenia, a dysfunctional antibody response, antibiotic drug resistance and poor response to immunization, SCD patients have impaired immunity. A leading cause of hospitalization and death in SCD patients is the acute chest syndrome (ACS). This complication is especially manifested upon infection of SCD patients with ()-a facultative anaerobic Gram-positive bacterium that causes lower respiratory tract infections. has developed increased rates of antibiotics resistance and is particularly virulent in SCD patients. The primary defense against is the generation of reactive oxygen species (ROS) during the oxidative burst of neutrophils and macrophages. Paradoxically, itself produces high levels of the ROS hydrogen peroxide (HO) as a virulence strategy. Apart from HO, also secretes another virulence factor, i.e., the pore-forming exotoxin pneumolysin (PLY), a potent mediator of lung injury in patients with pneumonia in general and particularly in those with SCD. PLY is released early on in infection either by autolysis or bacterial lysis following the treatment with antibiotics and has a broad range of biological activities. This review will discuss recent findings on the role of pneumococci in ACS pathogenesis and on strategies to counteract the devastating effects of its virulence factors on the lungs in SCD patients.

Citing Articles

Infections in sickle cell disease.

Scourfield L, Nardo-Marino A, Williams T, Rees D Haematologica. 2024; 110(3):546-561.

PMID: 39568431 PMC: 11873697. DOI: 10.3324/haematol.2024.285066.


Unraveling the full impact of SPD_0739: a key effector in iron homeostasis.

Womack E, Antone M, Eichenbaum Z Microbiol Spectr. 2024; :e0133124.

PMID: 39470285 PMC: 11620282. DOI: 10.1128/spectrum.01331-24.


Endogenously produced HO is intimately involved in iron metabolism in .

Womack E, Alibayov B, Vidal J, Eichenbaum Z Microbiol Spectr. 2023; 12(1):e0329723.

PMID: 38038454 PMC: 10783112. DOI: 10.1128/spectrum.03297-23.


Identification of phytochemical compounds of and their targets by metabolomics, network pharmacology and molecular docking studies.

Zhang M, Zhang X, Pei J, Guo B, Zhang G, Li M Heliyon. 2023; 9(3):e14029.

PMID: 36911881 PMC: 9977108. DOI: 10.1016/j.heliyon.2023.e14029.


Wogonin attenuates the pathogenicity of Streptococcus pneumoniae by double-target inhibition of Pneumolysin and Sortase A.

Gu K, Ding L, Wang Z, Sun Y, Sun X, Yang W J Cell Mol Med. 2023; 27(4):563-575.

PMID: 36747468 PMC: 9930429. DOI: 10.1111/jcmm.17684.


References
1.
Morgan T, Tomich E . Overwhelming post-splenectomy infection (OPSI): a case report and review of the literature. J Emerg Med. 2012; 43(4):758-63. DOI: 10.1016/j.jemermed.2011.10.029. View

2.
Los F, Randis T, Aroian R, Ratner A . Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev. 2013; 77(2):173-207. PMC: 3668673. DOI: 10.1128/MMBR.00052-12. View

3.
Lucas R, Czikora I, Sridhar S, Zemskov E, Gorshkov B, Siddaramappa U . Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs. Toxins (Basel). 2013; 5(7):1244-60. PMC: 3737495. DOI: 10.3390/toxins5071244. View

4.
Witzenrath M, Gutbier B, Hocke A, Schmeck B, Hippenstiel S, Berger K . Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med. 2006; 34(7):1947-54. DOI: 10.1097/01.CCM.0000220496.48295.A9. View

5.
Styles L, Aarsman A, Vichinsky E, Kuypers F . Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease. Blood. 2000; 96(9):3276-8. View